The genetic, clinical and immune landscape of clonal hematopoiesis across adulthood in the multi-ancestry Mount Sinai Million cohort
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP), the age-associated expansion of blood cell clones carrying acquired driver mutations, remains less well characterized in young adults, across genetic ancestries, and in clinical populations. We analyzed whole-exome sequencing and longitudinal electronic health record (EHR) data from 59,598 adults in the Mount Sinai Million Health Discoveries Program, an urban, multi-ancestry hospital-based cohort that includes substantial representation of African ([~]35%) and Admixed American genetic ancestry ([~]15%) and young adults aged 18-39 years ([~]30%). After sample QC, separate analyses were performed in discovery (n = 28,051) and validation (n = 26,938) cohorts defined by sequencing platform and combined by meta-analysis.
CHIP was detected in 8.5% of participants in each cohort and in 4.0% of young adults, with DNMT3A, TET2, ASXL1, and PPM1D the most frequently mutated genes. Prevalence and clone size increased with age across ancestry groups. After adjusting for age, participants of African ancestry had lower CHIP prevalence than those of European ancestry in both cohorts (discovery: OR=0.86, 95% CI = 0.78-0.95, p=0.002; validation: OR=0.84, 95% CI = 0.75-0.93, p=0.001). Participants of Admixed American ancestry showed a similar trend.
Higher systemic immune-inflammation index (SII) was associated with CHIP after adjusting for age, sex and ancestry in both cohorts (pooled OR=1.30, 95% CI = 1.15-1.48, p=4.78e-5). Heterozygosity at an HLA class II locus HLA-DPA1 was associated with 7% lower odds of overall CHIP (pooled OR=0.93, 95% CI = 0.87-0.99, p=0.03). Driver-stratified analyses revealed distinct HLA class II nominal association patterns for DNMT3A- and TET2-mutant CHIP. Particularly, HLA-DQB1 heterozygosity associated with lower odds of TET2-mutant CHIP (pooled OR=0.84, 95% CI = 0.70-1.00, p=0.05), HLA-DQA1 and HLA-DOB heterozygosity associated with higher odds of DNMT3A-mutant CHIP (pooled OR=1.19, 95% CI = 1.00-1.42, p=0.05; pooled OR=1.12, 95% CI = 1.01-1.25, p=0.03 respectively). Longitudinal EHR analyses revealed CHIP associations with several incident diseases that varied by driver gene and clone size. The broadest pattern of associations involved high-risk CHIP genes and encompassed hematologic malignancies, solid tumors, cardiovascular outcomes, hypertension, and COPD. High-VAF clones were the main drivers of these associations. Among adults aged [≥]40 years, phenome-wide analyses identified a Bonferroni-significant association with incident myeloproliferative disease and nominal associations with incident pancytopenia, anemia, cardiomegaly, and chronic renal failure. Young-adult CHIP was nominally associated with incident nodular goiter and esophageal disease. These findings characterize CHIP across adulthood and genetic ancestry and reveal inherited immune variation and systemic inflammation as correlates in a hospital-based population.
Related
- Heavy Drinking in Young Adulthood Correlates With Earlier Genetic Cardiomyopathy Diagnosis: Analyzing a Retrospective Survey.
- Compositional analysis of genetic ancestry shows that relative proportion of African ancestry is positively associated with fecal myeloperoxidase in Brazilian infants
- Multi-ancestry MHC-pQTL mapping reveals disease-linked HLA protein networks and shared genetic architecture
- Genetic ancestry shapes context-dependent immune regulation across Indigenous South American populations
- Multi-Ancestry Genome-wide Association Analyses Identify Shared and Specific Genetic Architecture in Mild and Moderate-to-Severe Asthma
BibTeX
@misc{selvan2026genetic,
title = {{The genetic, clinical and immune landscape of clonal hematopoiesis across adulthood in the multi-ancestry Mount Sinai Million cohort}},
author = {M. Esai Selvan and N. Ashraf and R. Pradeep and L. Giordano and M. Dougherty and P. Chevelev and C. J. Neuse and D. I. Nathan and B. K. Marcellino and R. J. Klein and Z. H. Gümüs},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.22.26366221},
url = {https://www.medrxiv.org/content/10.64898/2026.10.22.26366221v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - The genetic, clinical and immune landscape of clonal hematopoiesis across adulthood in the multi-ancestry Mount Sinai Million cohort
AU - M. Esai Selvan
AU - N. Ashraf
AU - R. Pradeep
AU - L. Giordano
AU - M. Dougherty
AU - P. Chevelev
AU - C. J. Neuse
AU - D. I. Nathan
AU - B. K. Marcellino
AU - R. J. Klein
AU - Z. H. Gümüs
PY - 2026
DA - 2026/10/22
PB - medRxiv
DO - 10.64898/2026.10.22.26366221
UR - https://www.medrxiv.org/content/10.64898/2026.10.22.26366221v1
AB - Clonal hematopoiesis of indeterminate potential (CHIP), the age-associated expansion of blood cell clones carrying acquired driver mutations, remains less well characterized in young adults, across genetic ancestries, and in clinical populations. We analyzed whole-exome sequencing and longitudinal electronic health record (EHR) data from 59,598 adults in the Mount Sinai Million Health Discoveries Program, an urban, multi-ancestry hospital-based cohort that includes substantial representation of African ([~]35%) and Admixed American genetic ancestry ([~]15%) and young adults aged 18-39 years ([~]30%). After sample QC, separate analyses were performed in discovery (n = 28,051) and validation (n = 26,938) cohorts defined by sequencing platform and combined by meta-analysis. CHIP was detected in 8.5% of participants in each cohort and in 4.0% of young adults, with DNMT3A, TET2, ASXL1, and PPM1D the most frequently mutated genes. Prevalence and clone size increased with age across ancestry groups. After adjusting for age, participants of African ancestry had lower CHIP prevalence than those of European ancestry in both cohorts (discovery: OR=0.86, 95% CI = 0.78-0.95, p=0.002; validation: OR=0.84, 95% CI = 0.75-0.93, p=0.001). Participants of Admixed American ancestry showed a similar trend. Higher systemic immune-inflammation index (SII) was associated with CHIP after adjusting for age, sex and ancestry in both cohorts (pooled OR=1.30, 95% CI = 1.15-1.48, p=4.78e-5). Heterozygosity at an HLA class II locus HLA-DPA1 was associated with 7% lower odds of overall CHIP (pooled OR=0.93, 95% CI = 0.87-0.99, p=0.03). Driver-stratified analyses revealed distinct HLA class II nominal association patterns for DNMT3A- and TET2-mutant CHIP. Particularly, HLA-DQB1 heterozygosity associated with lower odds of TET2-mutant CHIP (pooled OR=0.84, 95% CI = 0.70-1.00, p=0.05), HLA-DQA1 and HLA-DOB heterozygosity associated with higher odds of DNMT3A-mutant CHIP (pooled OR=1.19, 95% CI = 1.00-1.42, p=0.05; pooled OR=1.12, 95% CI = 1.01-1.25, p=0.03 respectively). Longitudinal EHR analyses revealed CHIP associations with several incident diseases that varied by driver gene and clone size. The broadest pattern of associations involved high-risk CHIP genes and encompassed hematologic malignancies, solid tumors, cardiovascular outcomes, hypertension, and COPD. High-VAF clones were the main drivers of these associations. Among adults aged [≥]40 years, phenome-wide analyses identified a Bonferroni-significant association with incident myeloproliferative disease and nominal associations with incident pancytopenia, anemia, cardiomegaly, and chronic renal failure. Young-adult CHIP was nominally associated with incident nodular goiter and esophageal disease. These findings characterize CHIP across adulthood and genetic ancestry and reveal inherited immune variation and systemic inflammation as correlates in a hospital-based population.
ER -